Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to -$109.9 million.

  • CorMedix's Net Cash Flow fell 172966.39% to -$109.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 26711.14%. This contributed to the annual value of -$3.1 million for FY2024, which is 78785.38% down from last year.
  • As of Q3 2025, CorMedix's Net Cash Flow stood at -$109.9 million, which was down 172966.39% from $93.0 million recorded in Q2 2025.
  • CorMedix's 5-year Net Cash Flow high stood at $93.0 million for Q2 2025, and its period low was -$109.9 million during Q3 2025.
  • Over the past 5 years, CorMedix's median Net Cash Flow value was -$4.4 million (recorded in 2021), while the average stood at -$682639.6.
  • Over the last 5 years, CorMedix's Net Cash Flow had its largest YoY gain of 148533.97% in 2025, and its largest YoY loss of 172966.39% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Net Cash Flow stood at -$13.0 million in 2021, then skyrocketed by 99.15% to -$111121.0 in 2022, then tumbled by 15990.82% to -$17.9 million in 2023, then soared by 130.01% to $5.4 million in 2024, then tumbled by 2148.64% to -$109.9 million in 2025.
  • Its Net Cash Flow was -$109.9 million in Q3 2025, compared to $93.0 million in Q2 2025 and $25.6 million in Q1 2025.